The FDA's Center for Biologics Evaluation and Research is planning to release some crucial guidance soon for CRISPR and gene therapy developers on platform technologies, accelerated ...
READ MORENeurocrine Biosciences’ newly-debuted campaign acknowledges the frustration that congenital adrenal hyperplasia (CAH) patients, families and endocrinologists often feel.
READ MOREImmunityBio scored an FDA approval for its once-rejected drug combo for bladder cancer, the biotech announced Monday, sending its stock up nearly 25% in premarket trading.
READ MOREThermo Fisher said it will be a “long-term beneficiary” of biopharma customers localizing their supply chains, given most of its network is based in the US and Europe.
READ MORE